p28 peptide p28 - p21-peptide-uses P28 The Promising Potential of the p28 Peptide in Cancer Therapy

ozempic-peptide-science The p28 peptide is emerging as a significant player in the field of oncology, demonstrating remarkable potential as a therapeutic agent against various solid tumors. Derived from the bacterial protein azurin, this cell-penetrating peptide (CPP), specifically a 28 amino acid fragment (amino acids 50-77), exhibits a unique ability to preferentially enter cancer cells, making it a promising candidate for innovative cancer treatments. Its therapeutic action is primarily linked to its interaction with the tumor suppressor protein p53, a crucial regulator of cell cycle arrest and apoptosis作者：MA Warso·2013·被引用次数：209—A first-in-class, first-in-human, phase I trial ofp28, a non-HDM2-mediatedpeptideinhibitor of p53 ubiquitination in patients with advanced ....

Understanding the Mechanism of Action

At its core, the p28 peptide functions by modulating the activity of p53. Researchers have discovered that p28 binds to p53 within the cell nucleus, stabilizing this critical protein. This stabilization is achieved through several mechanisms, including the inhibition of p53 degradation. Specifically, p28 forms a complex with p53, which in turn reduces the proteasomal degradation of p53. This effectively increases the intracellular levels of functional p53, leading to enhanced cell cycle arrest and apoptotic cell death in cancer cellsAzurin-Based Peptide p28 Arrests the p53-HDM2 Interactions.

Furthermore, p28 acts as a peptide inhibitor of COP1 binding to p53. COP1 is an E3 ubiquitin ligase that targets p53 for degradation. By preventing this interaction, p28 further contributes to the accumulation and sustained activity of p53作者：T Yamada·2013·被引用次数：73—p28, a cell penetratingpeptide, binds to the DNA binding domain (DBD) of p53, inducing a post-translational increase in intracellular levels of wild type .... This action is distinct from the more commonly studied inhibition of the p53-HDM2 interaction, positioning p28 as a "first-in-class, non-HDM2-mediated peptide inhibitor of p53 ubiquitination." The azurin-derived p28 peptide has shown to inhibit p53-HDM2 interactions as well, adding another layer to its therapeutic strategyAzurin p28 peptide (7662) by Tocris, Part of Bio-Techne.

Key Properties and Characteristics of p28

The p28 peptide is characterized by several key properties that contribute to its therapeutic efficacy:

* Cell-Penetrating Ability: As a cell-penetrating peptide (CPP), p28 can efficiently cross cell membranes, allowing it to reach its intracellular targets. This is a significant advantage over many conventional chemotherapeutic agents that struggle with cellular uptake. The anionic CPP nature of p28 is particularly noted for its preferential entry into cancer cells.

* Tumor Selectivity: p28 demonstrates a remarkable preference for solid tumor cells, minimizing damage to healthy tissues.作者：A Joy·2026—This study investigates the potential anticancer activity of the azurin-derivedpeptide p28through its molecular interactions with human double ... This tumor-targeting capability is crucial for reducing off-target effects and improving patient outcomes. The tumor-penetrated antitumor peptide designation highlights this crucial characteristic.

* Amphipathic and α-Helical Structure: p28 is an amphipathic, α-helical peptide.作者：H Abuei·2022·被引用次数：4—In this study, we aimed to maximize the expression of “biologically active”p28in Escherichia coli BL21 (DE3) host by harnessing statistical tools and ... This structural feature is believed to be important for its interaction with cell membranes and its ability to bind to p53. The N-terminal segment of p28 (residues 54 to 67) forms an alpha-helix.Solution structure of the anticancer p28 peptide in ...

* Small Size and Stability: Composed of 28 amino acids and having a molecular weight of approximately 2.9 kD, p28 is a relatively small and stable molecule. This small size facilitates its penetration into tumor tissues.

Clinical Investigations and Therapeutic Applications

The potential of the p28 peptide is being actively explored in clinical trialsPhase I trial of p28 (NSC745104), a non-HDM2-mediated .... Early-stage studies, including Phase I trials, have investigated the safety and tolerability of p28 in patients with recurrent or progressive cancersMayo Clinic discovers new role for protein to fight tumors. These trials have provided valuable data on the drug p28, a cancer cell killing peptide, and its impact on p53-positive cancers.

Beyond its direct application, p28 is also being investigated as a sensitizing agent to enhance the efficacy of existing chemotherapeutic drugs. For instance, its use in combination with current agents for glioblastoma multiforme (GBM) is being explored to improve treatment outcomesAzurin p28 peptide 897026-25-4. The ability of p28 to induce apoptosis or cell cycle arrest, and to inhibit p53-positive tumor growths, makes it a versatile therapeutic tool.

Future Directions and Research

The ongoing research into the p28 peptide continues to uncover new insights into its multifaceted anticancer actions作者：F Cantini·2021·被引用次数：4—In a mixed 50/50 HFA/H2O (vol/vol) solution,p28consists of a N-terminal segment (residues 54 to 67) that forms an α-helix, followed by a C- .... Studies are focusing on optimizing its production, as demonstrated by efforts to maximize the expression of biologically active p28 in host organisms like *Escherichia coli*.Mechanism of action of p28, a first-in-class, non-HDM2 ... Understanding the precise molecular interactions of p28, such as its engagement with the HDM2 N-terminal domain, is critical for further drug development.

The p28 peptide represents a significant advancement in the development of novel peptide-based agents for cancer treatment. Its unique mechanism of action, targeting the crucial p53 pathway, coupled with its tumor-selective and cell-penetrating properties, positions it as a highly promising therapeutic candidate with the potential to revolutionize cancer therapy. The exploration of azurin and its derived peptides, particularly p28, continues to yield exciting results in the fight against cancer.